BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure

Creative Commons License

Ozcelik S., Bircan R., Sarikaya S., Gul A. E., Aydin B., Ozcelik M., ...Daha Fazla

ENDOKRYNOLOGIA POLSKA, cilt.70, ss.401-408, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5603/ep.a2019.0025
  • Dergi Adı: ENDOKRYNOLOGIA POLSKA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.401-408
  • Anahtar Kelimeler: papillary thyroid cancer, BRAF V600E, iodine, BRAF V600E MUTATION, BRAF(V600E) MUTATION, PREVALENCE, CARCINOMA, ASSOCIATION, RECURRENCE, GENE
  • Marmara Üniversitesi Adresli: Evet

Özet

Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAF(V600E )mutation and well-established prognostic clinicopathological characteristics as well as iodine exposure.